COSCIENS Biopharma Net Income
| CSCI Stock | 2.05 0.05 2.38% |
As of the 5th of February, COSCIENS Biopharma shows the risk adjusted performance of 0.0155, and Mean Deviation of 6.75. COSCIENS Biopharma technical analysis gives you the methodology to make use of historical prices and volume patterns to determine a pattern that approximates the direction of the firm's future prices.
COSCIENS Biopharma Total Revenue |
|
Gross Profit | Profit Margin | Market Capitalization | Enterprise Value Revenue 0.1389 | Revenue |
| Last Reported | Projected for Next Year | ||
| Net Loss | -17.6 M | -16.7 M | |
| Net Loss | -13.8 M | -13.1 M | |
| Net Loss | (5.34) | (5.07) | |
| Net Income Per E B T | 0.90 | 0.65 |
COSCIENS | Net Income | Build AI portfolio with COSCIENS Stock |
The Net Income trend for COSCIENS Biopharma offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether COSCIENS Biopharma is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest COSCIENS Biopharma's Net Income Growth Pattern
Below is the plot of the Net Income of COSCIENS Biopharma over the last few years. Net income is one of the most important fundamental items in finance. It plays a large role in COSCIENS Biopharma financial statement analysis. It represents the amount of money remaining after all of COSCIENS Biopharma operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue. It is COSCIENS Biopharma's Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in COSCIENS Biopharma's overall financial position and show how it may be relating to other accounts over time.
| View | Last Reported (15.31 M) | 10 Years Trend |
|
Net Income |
| Timeline |
COSCIENS Net Income Regression Statistics
| Arithmetic Mean | (2,490,545) | |
| Coefficient Of Variation | (280.84) | |
| Mean Deviation | 5,102,547 | |
| Median | (231,667) | |
| Standard Deviation | 6,994,415 | |
| Sample Variance | 48.9T | |
| Range | 21.2M | |
| R-Value | (0.61) | |
| Mean Square Error | 32.9T | |
| R-Squared | 0.37 | |
| Significance | 0.01 | |
| Slope | (841,320) | |
| Total Sum of Squares | 782.7T |
COSCIENS Net Income History
Other Fundumenentals of COSCIENS Biopharma
COSCIENS Biopharma Net Income component correlations
COSCIENS Net Income Driver Correlations
Understanding the fundamental principles of building solid financial models for COSCIENS Biopharma is extremely important. It helps to project a fair market value of COSCIENS Stock properly, considering its historical fundamentals such as Net Income. Since COSCIENS Biopharma's main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of COSCIENS Biopharma's historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of COSCIENS Biopharma's interrelated accounts and indicators.
Click cells to compare fundamentals
Is there potential for Biotechnology market expansion? Will COSCIENS introduce new products? Factors like these will boost the valuation of COSCIENS Biopharma. Projected growth potential of COSCIENS fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.54) | Revenue Per Share | Quarterly Revenue Growth 0.176 | Return On Assets | Return On Equity |
Understanding COSCIENS Biopharma requires distinguishing between market price and book value, where the latter reflects COSCIENS's accounting equity. The concept of intrinsic value - what COSCIENS Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push COSCIENS Biopharma's price substantially above or below its fundamental value.
It's important to distinguish between COSCIENS Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding COSCIENS Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, COSCIENS Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
COSCIENS Biopharma 'What if' Analysis
In the world of financial modeling, what-if analysis is part of sensitivity analysis performed to test how changes in assumptions impact individual outputs in a model. When applied to COSCIENS Biopharma's stock what-if analysis refers to the analyzing how the change in your past investing horizon will affect the profitability against the current market value of COSCIENS Biopharma.
| 11/07/2025 |
| 02/05/2026 |
If you would invest 0.00 in COSCIENS Biopharma on November 7, 2025 and sell it all today you would earn a total of 0.00 from holding COSCIENS Biopharma or generate 0.0% return on investment in COSCIENS Biopharma over 90 days. COSCIENS Biopharma is related to or competes with Biora Therapeutics, CervoMed, and Tvardi Therapeutics. COSCIENS Biopharma is entity of United States More
COSCIENS Biopharma Upside/Downside Indicators
Understanding different market momentum indicators often help investors to time their next move. Potential upside and downside technical ratios enable traders to measure COSCIENS Biopharma's stock current market value against overall market sentiment and can be a good tool during both bulling and bearish trends. Here we outline some of the essential indicators to assess COSCIENS Biopharma upside and downside potential and time the market with a certain degree of confidence.
| Downside Deviation | 13.65 | |||
| Information Ratio | 0.0036 | |||
| Maximum Drawdown | 94.83 | |||
| Value At Risk | (28.04) | |||
| Potential Upside | 27.11 |
COSCIENS Biopharma Market Risk Indicators
Today, many novice investors tend to focus exclusively on investment returns with little concern for COSCIENS Biopharma's investment risk. Other traders do consider volatility but use just one or two very conventional indicators such as COSCIENS Biopharma's standard deviation. In reality, there are many statistical measures that can use COSCIENS Biopharma historical prices to predict the future COSCIENS Biopharma's volatility.| Risk Adjusted Performance | 0.0155 | |||
| Jensen Alpha | 0.104 | |||
| Total Risk Alpha | (0.94) | |||
| Sortino Ratio | 0.0037 | |||
| Treynor Ratio | 6.52 |
Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of COSCIENS Biopharma's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
COSCIENS Biopharma February 5, 2026 Technical Indicators
| Cycle Indicators | ||
| Math Operators | ||
| Math Transform | ||
| Momentum Indicators | ||
| Overlap Studies | ||
| Pattern Recognition | ||
| Price Transform | ||
| Statistic Functions | ||
| Volatility Indicators | ||
| Volume Indicators |
| Risk Adjusted Performance | 0.0155 | |||
| Market Risk Adjusted Performance | 6.53 | |||
| Mean Deviation | 6.75 | |||
| Semi Deviation | 11.44 | |||
| Downside Deviation | 13.65 | |||
| Coefficient Of Variation | 12213.73 | |||
| Standard Deviation | 14.03 | |||
| Variance | 196.96 | |||
| Information Ratio | 0.0036 | |||
| Jensen Alpha | 0.104 | |||
| Total Risk Alpha | (0.94) | |||
| Sortino Ratio | 0.0037 | |||
| Treynor Ratio | 6.52 | |||
| Maximum Drawdown | 94.83 | |||
| Value At Risk | (28.04) | |||
| Potential Upside | 27.11 | |||
| Downside Variance | 186.29 | |||
| Semi Variance | 130.79 | |||
| Expected Short fall | (8.07) | |||
| Skewness | 1.37 | |||
| Kurtosis | 7.23 |
COSCIENS Biopharma Backtested Returns
COSCIENS Biopharma is abnormally volatile at the moment. COSCIENS Biopharma secures Sharpe Ratio (or Efficiency) of 0.0106, which signifies that the company had a 0.0106 % return per unit of volatility over the last 3 months. We have found twenty-nine technical indicators for COSCIENS Biopharma, which you can use to evaluate the volatility of the firm. Please confirm COSCIENS Biopharma's risk adjusted performance of 0.0155, and Mean Deviation of 6.75 to double-check if the risk estimate we provide is consistent with the expected return of 0.15%. The firm shows a Beta (market volatility) of 0.0161, which signifies not very significant fluctuations relative to the market. As returns on the market increase, COSCIENS Biopharma's returns are expected to increase less than the market. However, during the bear market, the loss of holding COSCIENS Biopharma is expected to be smaller as well. COSCIENS Biopharma currently shows a risk of 14.48%. Please confirm COSCIENS Biopharma semi variance, and the relationship between the maximum drawdown and accumulation distribution , to decide if COSCIENS Biopharma will be following its price patterns.
Auto-correlation | -0.26 |
Weak reverse predictability
COSCIENS Biopharma has weak reverse predictability. Overlapping area represents the amount of predictability between COSCIENS Biopharma time series from 7th of November 2025 to 22nd of December 2025 and 22nd of December 2025 to 5th of February 2026. The more autocorrelation exist between current time interval and its lagged values, the more accurately you can make projection about the future pattern of COSCIENS Biopharma price movement. The serial correlation of -0.26 indicates that nearly 26.0% of current COSCIENS Biopharma price fluctuation can be explain by its past prices.
| Correlation Coefficient | -0.26 | |
| Spearman Rank Test | -0.01 | |
| Residual Average | 0.0 | |
| Price Variance | 0.07 |
Because income is reported on the Income Statement of a company and is measured in dollars some investors prefer to use Profit Margin, which measures income as a percentage of sales.
| Competition |
COSCIENS Accumulated Other Comprehensive Income
Accumulated Other Comprehensive Income |
|
Based on the recorded statements, COSCIENS Biopharma reported net income of (15.31 Million). This is 104.49% lower than that of the Biotechnology sector and 121.86% lower than that of the Health Care industry. The net income for all United States stocks is 102.68% higher than that of the company.
COSCIENS Net Income Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses COSCIENS Biopharma's direct or indirect competition against its Net Income to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of COSCIENS Biopharma could also be used in its relative valuation, which is a method of valuing COSCIENS Biopharma by comparing valuation metrics of similar companies.COSCIENS Biopharma is currently under evaluation in net income category among its peers.
COSCIENS Biopharma Current Valuation Drivers
We derive many important indicators used in calculating different scores of COSCIENS Biopharma from analyzing COSCIENS Biopharma's financial statements. These drivers represent accounts that assess COSCIENS Biopharma's ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of COSCIENS Biopharma's important valuation drivers and their relationship over time.
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 (projected) | ||
| Market Cap | 83.4M | 31.7M | 18.4M | 7.2M | 8.2M | 7.8M | |
| Enterprise Value | 79.4M | 23.4M | 11.8M | (5.9M) | (6.8M) | (6.5M) |
COSCIENS Fundamentals
| Return On Equity | -1.13 | ||||
| Return On Asset | -0.17 | ||||
| Profit Margin | (2.00) % | ||||
| Operating Margin | (0.86) % | ||||
| Current Valuation | 1.31 M | ||||
| Shares Outstanding | 3.18 M | ||||
| Shares Owned By Insiders | 1.48 % | ||||
| Shares Owned By Institutions | 8.93 % | ||||
| Number Of Shares Shorted | 9.91 K | ||||
| Price To Book | 1.17 X | ||||
| Price To Sales | 0.92 X | ||||
| Revenue | 13.78 M | ||||
| Gross Profit | 4.42 M | ||||
| EBITDA | (13.49 M) | ||||
| Net Income | (15.31 M) | ||||
| Total Debt | 2.31 M | ||||
| Book Value Per Share | 2.23 X | ||||
| Cash Flow From Operations | (14.57 M) | ||||
| Short Ratio | 1.67 X | ||||
| Earnings Per Share | (6.54) X | ||||
| Number Of Employees | 40 | ||||
| Beta | 1.85 | ||||
| Market Capitalization | 8.64 M | ||||
| Total Asset | 35.07 M | ||||
| Retained Earnings | (12.11 M) | ||||
| Working Capital | 16.76 M | ||||
| Net Asset | 35.07 M |
About COSCIENS Biopharma Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze COSCIENS Biopharma's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of COSCIENS Biopharma using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of COSCIENS Biopharma based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Currently Active Assets on Macroaxis
| FSLY | Fastly Class A | |
| MOB | Mobilicom Limited American | |
| CMG | Chipotle Mexican Grill | |
| CSAN | Cosan SA ADR | |
| RKT | Rocket Companies |
Check out For more detail on how to invest in COSCIENS Stock please use our How to Invest in COSCIENS Biopharma guide.You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.
Is there potential for Biotechnology market expansion? Will COSCIENS introduce new products? Factors like these will boost the valuation of COSCIENS Biopharma. Projected growth potential of COSCIENS fundamentally drives upward valuation adjustments. Understanding fair value requires weighing current performance against future potential. All the valuation information about COSCIENS Biopharma listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (6.54) | Revenue Per Share | Quarterly Revenue Growth 0.176 | Return On Assets | Return On Equity |
Understanding COSCIENS Biopharma requires distinguishing between market price and book value, where the latter reflects COSCIENS's accounting equity. The concept of intrinsic value - what COSCIENS Biopharma's is actually worth based on fundamentals - guides informed investors toward better entry and exit points. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Market sentiment, economic cycles, and investor behavior can push COSCIENS Biopharma's price substantially above or below its fundamental value.
It's important to distinguish between COSCIENS Biopharma's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding COSCIENS Biopharma should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. In contrast, COSCIENS Biopharma's trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.